publication venue for
- Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.. 57. 2020
- Integrating genomics into prognostic models for AML.. 51. 2014
- Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura.. 37. 2000
- Splenectomy-sparing, long-term maintenance with anti-D for chronic immune (idiopathic) thrombocytopenic purpura: the New York Hospital experience.. 37. 2000
- The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis.. 37. 2000
- Interferon alfa: effects of long-term treatment for polycythemia vera.. 34. 1997
- The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.. 25. 1988
- Advances in chemotherapy for large cell lymphoma.. 24. 1987
- The bone marrow in polycythemia vera.. 12. 1975
- Acquired lipidosis: Gaucher-like cells and "blue cells" in chronic granulocytic leukemia.. 9. 1972
- The regulation of porphyrin and heme synthesis.. 5. 1968
- Updates on the biology of chronic lymphocytic leukemia: introductory editorial.. 61. 2024
- Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial. 2024
- Delayed diagnosis of congenital sideroblastic anemia.. 55. 2017
- New thrombopoietic agents: introduction.. 47. 2010
- Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.. 38. 2001
- Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. 2018
- The epigenetic basis of diffuse large B-cell lymphoma. 2015
- Current status of the role of PET imaging in diffuse large B-cell lymphoma. 2015
- Thrombopoietin receptor agonists: a critical review. 2014
- Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 2001
- The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. 1998
- Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. 1998
- Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. 1998
- Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. 1997
- The natural history of chronic myelogenous leukemia in the interferon era. 1995
- The treatment of chronic lymphocytic leukemia. 1969
- The Management of older patients with Hodgkin lymphoma: implications of S1826. 2024
- Measurable residual disease after CAR T-cell therapy. 2023
- Genetic and epigenetic determinants of AML pathogenesis. 2018
- Mass spectrometry and proteomics in hematology. 2018
- Therapeutic targeting of RNA splicing in myelodysplasia. 2017
- Haploidentical cord transplantation-The best of both worlds. 2016
- Is there a role for "watch and wait" in patients with mantle cell lymphoma? 2011
- Unrelated umbilical cord blood unit selection. 2010
- Targeted treatment and new agents in diffuse large B-cell lymphoma. 2008
- Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. 2008
- Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. 2005
- Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. 2001
- Thrombophilias: diagnosis and treatment of thrombophilia relating to contraception and pregnancy. 1999
- Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. 1995